by Ryan Paolicelli | Jun 3, 2024
In today’s labor market, good help is hard to find. For companies developing antibiotics, it’s becoming nearly impossible. Three years ago, I became CEO of the AMR Action Fund, which is investing approximately $1 billion in biotech companies developing treatments for...
by Ryan Paolicelli | May 30, 2024
Europe’s pipeline of new antibiotics to tackle the growing antimicrobial resistance (AMR) crisis remains inadequate. Belgium is developing a new antibiotic class, but success depends on securing vital support and incentives. A recent report by the International...
by Ryan Paolicelli | Mar 4, 2024
The AMR Industry Alliance this week issued a “call-to-action” in advance of the United Nations (UN) High-Level Meeting on AMR (antimicrobial resistance) in September. The document from the Alliance, which represents companies and trade associations from...
by Ryan Paolicelli | Feb 28, 2024
Pharmaceutical company Viatris announced today that its manufacturing site in India has received Minimized Risk of Antimicrobial Resistance (AMR) certification. The certification, developed by the British Standards Institution (BSI) in collaboration with the AMR...
by Ryan Paolicelli | Feb 28, 2024
Antimicrobial resistance (AMR) is a leading cause of death worldwide. In 2019 alone, AMR directly resulted in about 1.27 million deaths, and played a role in almost 5 million deaths. Without intervention, that death toll is expected to rise to about 10 million deaths...